Table 1 Characteristics of Phase 1 and 2 cohorts
From: Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
Phase 1 cohort | Phase 2 cohort | |||
|---|---|---|---|---|
Number of patients (%) | Median (range) | Number of patients (%) | Median (range) | |
Age (years) | 97 (100) | 65 (46–87) | 87 (100) | 72 (40–89) |
Follow-up (months) | 97 (100) | 14 (3–63) | 15 (0.7–45) | |
Status | ||||
Alive | 16 (16) | 34 (39) | ||
Dead | 81 (84) | 53 (61) | ||
PSA response | ||||
Partial response | 61 (63) | 38 (44) | ||
Stable disease | 25 (26) | 22 (25) | ||
Progressive disease | 11 (11) | 19 (22) | ||
Unknown | — | 8 (9) | ||
Survival (months) | ||||
All patients | 17 (3–63) | 20 (1–45) | ||
Partial response | 24 (3–63) | 23 (2–45) | ||
Stable disease | 12 (5–28) | 18 (1–30) | ||
Progressive disease | 9 (3–29) | 13 (2–32) | ||
Gleason at diagnosis | ||||
<7 | 7 (7) | 6 (7) | ||
7 | 24 (25) | 18 (21) | ||
>7 | 50 (52) | 39 (45) | ||
Unknown | 16 (16) | 24 (27) | ||
Serum PSA, baseline (μg l−1) | 96 (99) | 145 (0.6–3882) | 84 (97) | 96 (1.1–10054) |
Haemoglobin, baseline (g l−1) | 97 (100) | 124 (67–162) | 84 (97) | 125 (79–168) |
Alkaline Phosphatase, baseline (U l−1) | 90 (93) | 141 (15–2962) | 82 (85) | 132 (16–2199) |
Metastasis | ||||
None | 5(5) | 1 (1) | ||
Bone only | 53 (55) | 54 (62) | ||
Soft tissuea | 39 (40) | 29 (34) | ||
Unknown | — | 3 (3) | ||
Subsequent treatments | ||||
Cabazitaxel | 22 (23) | 29 (33) | ||
Abiraterone | 30 (31) | 50 (57) | ||
Enzalutamide | 2 (2) | 21 (24) | ||
Mitoxantrone | 12 (12) | 10 (11) | ||
Otherb | 1 (1) | 9 (10) | ||
Unknown | 32 (33) | 6 (7) | ||
